Improve walking speed with vibrotactile
- Trial ID
- NCT07308418
- Official Title
- The Influence of Vibrotactile Stimulation on Self-selected Walking Speed in People With Parkinson's Disease
- Goal
- Improve walking speed with vibrotactile
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Magnes AG
- Study Type
- INTERVENTIONAL
- Enrollment
- 16 participants
- Conditions
- Parkinson's Disease (PD)
- Interventions
- Vibrotactile feedback during walking
Plain-Language Summary
The goal is to see whether gentle vibration cues can help people with Parkinson's walk faster at their usual pace, by improving step timing and cadence that often become slow or irregular. The approach uses wearable vibrotactile feedback during walking, delivering gentle rhythmic vibrations as an external sensory cue to boost gait timing; it is not a drug and does not change levodopa or other dopaminergic therapy, so participants stay on stable medication. The trial is looking for adults 18 and older with a medically confirmed Parkinson's diagnosis who can walk at least 200 meters, have had no change in dopaminergic meds for at least four weeks, and can understand German; people with atypical parkinsonism, sensory loss in the feet, other major conditions affecting walking, or significant cognitive impairment are excluded.
Locations
- Magnes AG, Zurich, Canton of Zurich, Switzerland
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Vibrotactile feedback during walking. The goal is to see whether gentle vibration cues can help people with Parkinson's walk faster at their usual pace, by improving step timing and cadence that often become slow or irregular. The approach uses wearable vibrotactile feedback during walking, delivering gentle rhythmic vibrations as an external sensory cue to boost gait timing; it is not a drug and does not change levodopa or other dopaminergic therapy, so participants stay on stable medication. The trial is looking for adults 18 and older with a medically confirmed Parkinson's diagnosis who can walk at least 200 meters, have had no change in dopaminergic meds for at least four weeks, and can understand German; people with atypical parkinsonism, sensory loss in the feet, other major conditions affecting walking, or significant cognitive impairment are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 months.